Hubbell vs 10X Genomics Inc — how do they compare? Hubbell trades at $475.77 (market cap $25.12B), while 10X Genomics Inc trades at $79.3 (market cap $9.92B). The key difference: Hubbell is far larger — about 2.5× 10X Genomics Inc's market cap, and Hubbell pays a 1.19% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hubbell for 3 Days and 10X Genomics Inc for 92 Days on average.
| HUBB | TXG | |
|---|---|---|
Market Cap | $25.12B | $9.92B |
Volume | 503,522 | 9,372,166 |
Sector | Industrials | Health |
52-Week High | $557.85 | $97.74 |
52-Week Low | $407.36 | $11.48 |
Typical Hold Time | 3 Days | 92 Days |
Enterprise Value | $30.28B | $9.44B |
Dividend Yield | 1.19% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hubbell manufactures electrical and utility products used in transmission, distribution, and electrical infrastructure. Its portfolio includes components and systems for utilities, data centers, industrial facilities, and buildings.
Read more on HUBB →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →